FR07C0046I2 - BETA-L-2'-DESOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B - Google Patents

BETA-L-2'-DESOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B

Info

Publication number: FR07C0046I2
Authority: FR; France
Prior art keywords: desoxy; nucleosides; hepatitis; beta; treatment
Prior art date: 1998-08-10
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

FR07C0046C

Other languages

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Idenix Cayman Ltd

Original Assignee

Idenix Cayman Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-08-10

Filing date

2007-09-21

Publication date

2008-05-09

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26791121&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR07C0046(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-09-21 Application filed by Idenix Cayman Ltd filed Critical Idenix Cayman Ltd

2007-10-26 Publication of FR07C0046I1 publication Critical patent/FR07C0046I1/fr

2008-05-09 Application granted granted Critical

2008-05-09 Publication of FR07C0046I2 publication Critical patent/FR07C0046I2/en

Status Active legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Virology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Gastroenterology & Hepatology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Medicinal Preparation (AREA)

FR07C0046C 1998-08-10 2007-09-21 BETA-L-2'-DESOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B Active FR07C0046I2 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US9611098P	1998-08-10	1998-08-10
US13135299P	1999-04-28	1999-04-28
PCT/US1999/018149 WO2000009531A2 (en)	1998-08-10	1999-08-10	β-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B

Publications (2)

Publication Number	Publication Date
FR07C0046I1 FR07C0046I1 (en)	2007-10-26
FR07C0046I2 true FR07C0046I2 (en)	2008-05-09

Family

ID=26791121

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR07C0046C Active FR07C0046I2 (en)	1998-08-10	2007-09-21	BETA-L-2'-DESOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B

Country Status (21)

Country	Link
US (5)	US6395716B1 (en)
EP (2)	EP2415776B1 (en)
JP (2)	JP4294870B2 (en)
KR (4)	KR100568035B1 (en)
CN (3)	CN100482236C (en)
AT (1)	ATE313550T1 (en)
AU (1)	AU5475799A (en)
BR (1)	BRPI9912896B8 (en)
CA (1)	CA2340156C (en)
CY (2)	CY2007017I1 (en)
DE (2)	DE69929060T2 (en)
DK (3)	DK2415776T3 (en)
ES (3)	ES2579903T3 (en)
FR (1)	FR07C0046I2 (en)
LU (1)	LU91348I2 (en)
MX (1)	MXPA01001507A (en)
NL (1)	NL300286I2 (en)
PT (2)	PT2415776T (en)
RU (1)	RU2424016C2 (en)
SG (1)	SG132498A1 (en)
WO (1)	WO2000009531A2 (en)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4413996B2 (en) *	1995-06-07	2010-02-10	エモリー・ユニバーシティ	Nucleoside having anti-hepatitis B virus activity
US6444652B1 (en) *	1998-08-10	2002-09-03	Novirio Pharmaceuticals Limited	β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
ES2579903T3 (en) *	1998-08-10	2016-08-17	Centre National De La Recherche Scientifique (Cnrs)	Beta-L-2'-deoxy-nucleosides for the treatment of hepatitis B
EP1232166A2 (en) *	1999-11-12	2002-08-21	Pharmasset Limited	Synthesis of 2'-deoxy-l-nucleosides
EP1634888A3 (en)	1999-11-12	2007-11-21	Pharmasset, Inc.	Synthesis of 2'-deoxy-L-nucleosides
PL201411B1 (en) *	2000-02-29	2009-04-30	Bristol Myers Squibb Co	Low dose entecavir formulation and use
AU2001245575A1 (en) *	2000-03-09	2001-09-17	Videoshare, Inc.	Sharing a streaming video
US6822089B1 (en) *	2000-03-29	2004-11-23	Isis Pharmaceuticals, Inc.	Preparation of deoxynucleosides
ATE414520T1 (en) *	2000-04-13	2008-12-15	Pharmasset Inc	3 OR 2 HYDROXYMETHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AND THEIR USE FOR TREATING VIRUS INFECTIONS
MY164523A (en)	2000-05-23	2017-12-29	Univ Degli Studi Cagliari	Methods and compositions for treating hepatitis c virus
WO2001092282A2 (en) *	2000-05-26	2001-12-06	Idenix (Cayman) Limited	Methods and compositions for treating flaviviruses and pestiviruses
IL153078A0 (en)	2000-05-26	2003-06-24	Idenix Cayman Ltd	Methods for treating hepatitis delta virus infection with beta-l-2' deoxy nucleosides
US6787526B1 (en) *	2000-05-26	2004-09-07	Idenix Pharmaceuticals, Inc.	Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
MY141594A (en) *	2000-06-15	2010-05-14	Novirio Pharmaceuticals Ltd	3'-PRODRUGS OF 2'-DEOXY-ß-L-NUCLEOSIDES
US6875751B2 (en)	2000-06-15	2005-04-05	Idenix Pharmaceuticals, Inc.	3′-prodrugs of 2′-deoxy-β-L-nucleosides
CN102241720B (en) *	2000-11-29	2014-01-29	三井化学株式会社	L-nucleic acid derivative and processes for the synthesis thereof
CN101250208B (en) *	2000-11-29	2012-06-20	三井化学株式会社	L-nucleic acid derivative and processes for the synthesis thereof
WO2003053360A2 (en)	2001-12-20	2003-07-03	Pharmassett Ltd.	Treatment of ebv and khsv infection and associated abnormal cellular proliferation
CA2470521A1 (en) *	2001-12-21	2003-07-10	Micrologix Biotech Inc.	Anti-viral 7-deaza l-nucleosides
AU2003217863B9 (en) *	2002-02-28	2009-10-29	Biota Scientific Management Pty Ltd	Nucleotide mimics and their prodrugs
DE60303131T2 (en) *	2002-06-27	2006-07-20	Medivir Ab	SYNERGISTIC INTERACTION OF ABACAVIR AND ALOVUDIN
CN101172993A (en) *	2002-06-28	2008-05-07	埃迪尼克斯(开曼)有限公司	2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
DK1523489T3 (en)	2002-06-28	2014-06-16	Idenix Pharmaceuticals Inc	MODIFIED 2 'AND 3' NUCLEOSIDE PRODUCTS TO TREAT FLAVIRIDA INFECTIONS
BR0312278A (en) *	2002-06-28	2007-06-19	Idenix Cayman Ltd	2'-c-methyl-3'-o-1-valine ribofuranosyl cytidine ester for treatment of flaviviridae infections
PL374792A1 (en)	2002-06-28	2005-10-31	Idenix (Cayman) Limited	2' and 3'-nucleoside prodrugs for treating flaviviridae infections
US7608600B2 (en) *	2002-06-28	2009-10-27	Idenix Pharmaceuticals, Inc.	Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
TWI244393B (en) *	2002-08-06	2005-12-01	Idenix Pharmaceuticals Inc	Crystalline and amorphous forms of beta-L-2'-deoxythymidine
JP4173861B2 (en) *	2002-09-13	2008-10-29	イデニクス（ケイマン）リミテツド	Β-L-2'-deoxynucleoside and combination therapy for the treatment of resistant HBV strains
EP1556398B1 (en) *	2002-10-31	2009-09-09	Metabasis Therapeutics, Inc.	Novel cytarabine monophosphate prodrugs
KR20050088079A (en)	2002-11-15	2005-09-01	이데닉스 (케이만) 리미티드	2'-branched nucleosides and flaviviridae mutation
ES2470771T3 (en) *	2002-12-12	2014-06-24	Idenix Pharmaceuticals, Inc	Procedure for the production of branched nucleosides in 2 '
CN101415719A (en) *	2003-03-20	2009-04-22	微生物化学及药品有限公司	Methods of manufacture of 2 -deoxy-beta-L-nucleosides
EP1620451A4 (en) *	2003-04-28	2009-02-18	Novartis Ag	Industrially scalable nucleoside synthesis
WO2004096197A2 (en) *	2003-05-02	2004-11-11	Universita Degli Studi Di Cagliari	5-aza-7-deazapurine nucleosides for treating flaviviridae
BRPI0419345B8 (en)	2003-05-30	2021-05-25	Gilead Pharmasset Llc	use of (2'r)-2'-deoxy-2'-fluor-2'-c-methyl nucleoside and a pharmaceutical composition comprising it
JP2007527396A (en) *	2003-06-30	2007-09-27	イデニクス（ケイマン）リミテツド	Synthesis of β-L-2'-deoxynucleoside
CN1315863C (en) *	2003-12-12	2007-05-16	河南省科学院质量检验与分析测试研究中心	Beta-2'-deoxygenation-ramification of nucleotide, synthetic method and application of medication
CN101023094B (en)	2004-07-21	2011-05-18	法莫赛特股份有限公司	Preparation of alkyl-substituted 2-deoxy-2-fluoro-d-ribofuranosyl pyrimidines and purines and their derivatives
CA2580457C (en)	2004-09-14	2014-11-04	Pharmasset, Inc.	Preparation of 2'fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
JP4516863B2 (en) *	2005-03-11	2010-08-04	株式会社ケンウッド	Speech synthesis apparatus, speech synthesis method and program
US8076303B2 (en)	2005-12-13	2011-12-13	Spring Bank Pharmaceuticals, Inc.	Nucleotide and oligonucleotide prodrugs
ES2422290T3 (en) *	2005-12-23	2013-09-10	Idenix Pharmaceuticals Inc	Procedure for preparing a synthetic intermediate for the preparation of branched nucleosides
WO2007133865A2 (en)	2006-04-11	2007-11-22	Novartis Ag	Hcv/hiv inhibitors an their uses
US7964580B2 (en)	2007-03-30	2011-06-21	Pharmasset, Inc.	Nucleoside phosphoramidate prodrugs
US20090082306A1 (en) *	2007-09-26	2009-03-26	Protia, Llc	Deuterium-enriched telbivudine
TW200946541A (en)	2008-03-27	2009-11-16	Idenix Pharmaceuticals Inc	Solid forms of an anti-HIV phosphoindole compound
US8551973B2 (en)	2008-12-23	2013-10-08	Gilead Pharmasset Llc	Nucleoside analogs
EP2671888A1 (en)	2008-12-23	2013-12-11	Gilead Pharmasset LLC	3',5'-cyclic nucleoside phosphate analogues
AR074897A1 (en)	2008-12-23	2011-02-23	Pharmasset Inc	NUCLEOSID PHOSPHORAMIDATES
US20110182850A1 (en)	2009-04-10	2011-07-28	Trixi Brandl	Organic compounds and their uses
US8512690B2 (en)	2009-04-10	2013-08-20	Novartis Ag	Derivatised proline containing peptide compounds as protease inhibitors
US8618076B2 (en)	2009-05-20	2013-12-31	Gilead Pharmasset Llc	Nucleoside phosphoramidates
TWI576352B (en)	2009-05-20	2017-04-01	基利法瑪席特有限責任公司	Nucleoside phosphoramidates
US8946244B2 (en) *	2009-11-16	2015-02-03	University Of Georgia Research Foundation, Inc.	2′-fluoro-6′methylene carbocyclic nucleosides and methods of treating viral infections
WO2011123645A2 (en)	2010-03-31	2011-10-06	Pharmasset, Inc.	Nucleoside phosphoramidates
JP5909495B2 (en)	2010-10-08	2016-04-26	ノバルティスアーゲー	Vitamin E formulation of sulfamide NS3 inhibitor
EP2646453A1 (en)	2010-11-30	2013-10-09	Gilead Pharmasset LLC	Compounds
CN102649788B (en) *	2011-02-28	2015-03-25	四川大学	Beta-L-2'-desoxy-thymin-nucleoside derivative, preparation method and purposes thereof
PL2709613T5 (en)	2011-09-16	2020-12-14	Gilead Pharmasset Llc	Methods for treating hcv
US8889159B2 (en)	2011-11-29	2014-11-18	Gilead Pharmasset Llc	Compositions and methods for treating hepatitis C virus
MY172166A (en)	2013-01-31	2019-11-15	Gilead Pharmasset Llc	Combination formulation of two antiviral compounds
JP2016529293A (en)	2013-08-27	2016-09-23	ギリアドファーマセットエルエルシー	Combination preparation of two antiviral compounds
CN114404427A (en)	2014-02-13	2022-04-29	配体药物公司	Prodrug compound and use thereof
WO2016003812A1 (en)	2014-07-02	2016-01-07	Ligand Pharmaceuticals, Inc.	Prodrug compounds and uses therof
CN111788196A (en)	2018-01-09	2020-10-16	配体药物公司	Acetal compounds and their therapeutic uses
CN110680806A (en) *	2018-07-04	2020-01-14	郑州泰丰制药有限公司	Preparation method of telbivudine particles
CN108570078A (en) *	2018-07-18	2018-09-25	荆门医药工业技术研究院	A method of preparing three-O- benzoyls-β of 1-O- acetyl group -2,3,5--D-RIBOSE
CN114133398B (en) *	2021-12-31	2022-11-22	中南民族大学	Amino acid substituted acyclovir tricyclic nucleoside derivative and synthesis method and application thereof

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB875971A (en)	1959-01-14	1961-08-30	Hoffmann La Roche	A process for the manufacture of uridine and thymidine derivatives and novel compounds concerned therein
US4522811A (en)	1982-07-08	1985-06-11	Syntex (U.S.A.) Inc.	Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5223263A (en)	1988-07-07	1993-06-29	Vical, Inc.	Liponucleotide-containing liposomes
US4916122A (en)	1987-01-28	1990-04-10	University Of Georgia Research Foundation, Inc.	3'-Azido-2',3'-dideoxyuridine anti-retroviral composition
US5190926A (en)	1987-01-28	1993-03-02	University Of Georgia Research Foundation, Inc.	3'-azido-2',3'-dideoxypyrimidines and related compounds as antiviral agents
GB8719367D0 (en)	1987-08-15	1987-09-23	Wellcome Found	Therapeutic compounds
WO1989002733A1 (en)	1987-09-22	1989-04-06	The Regents Of The University Of California	Liposomal nucleoside analogues for treating aids
US6020322A (en)	1993-11-09	2000-02-01	Pro-Neuron, Inc.	Acyl deoxyribonucleoside derivatives and uses thereof
DE3856557T2 (en)	1987-10-28	2004-06-03	Wellstat Therapeutics Corp.	Acyl deoxyribonucleoside derivatives and uses thereof
JP2675864B2 (en)	1988-07-05	1997-11-12	キヤノン株式会社	Recording material and inkjet recording method using the same
SE8802687D0 (en) *	1988-07-20	1988-07-20	Astra Ab	NUCLEOSIDE DERIVATIVES
US5194654A (en)	1989-11-22	1993-03-16	Vical, Inc.	Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5411947A (en)	1989-06-28	1995-05-02	Vestar, Inc.	Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5463092A (en)	1989-11-22	1995-10-31	Vestar, Inc.	Lipid derivatives of phosphonacids for liposomal incorporation and method of use
US5204466A (en)	1990-02-01	1993-04-20	Emory University	Method and compositions for the synthesis of bch-189 and related compounds
WO1991016920A1 (en)	1990-05-07	1991-11-14	Vical, Inc.	Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs
WO1991018914A1 (en)	1990-05-29	1991-12-12	Vical, Inc.	Synthesis of glycerol di- and triphosphate derivatives
DK0533833T3 (en)	1990-06-13	1996-04-22	Arnold Glazier	Phosphorus prodrugs
EP0543806B1 (en)	1990-07-12	1996-01-17	G-Drill Ab	Hydraulic down-the-hole rock drill
DE10399025I2 (en) *	1990-09-14	2007-11-08	Acad Of Science Czech Republic	Active substance precursors of phosphonates
US5206244A (en) *	1990-10-18	1993-04-27	E. R. Squibb & Sons, Inc.	Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines
US5543389A (en)	1990-11-01	1996-08-06	State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization	Covalent polar lipid-peptide conjugates for use in salves
US5256641A (en)	1990-11-01	1993-10-26	State Of Oregon	Covalent polar lipid-peptide conjugates for immunological targeting
US5149794A (en)	1990-11-01	1992-09-22	State Of Oregon	Covalent lipid-drug conjugates for drug targeting
US5543390A (en)	1990-11-01	1996-08-06	State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University	Covalent microparticle-drug conjugates for biological targeting
IT1246983B (en) *	1990-11-13	1994-12-12	Consiglio Nazionale Ricerche	L-2'-DESOXYURIDINE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT.
IL100502A (en)	1991-01-03	1995-12-08	Iaf Biochem Int	Pharmaceutical compositions containing cis-4-amino-1(hydroxymethyl-1,3-oxathiolan-5-yl)-1H-pyrimid-2-one nucleoside or its derivatives
DK0574487T3 (en)	1991-03-06	2002-10-14	Univ Emory	Use of 5-fluoro-2'-deoxy-thiacytidine in the treatment of hepatitis B
US5220003A (en)	1991-03-29	1993-06-15	The Regents Of The University Of California	Process for the synthesis of 2',3'-dideoxynucleosides
WO1992018517A1 (en)	1991-04-17	1992-10-29	Yale University	Method of treating or preventing hepatitis b virus
WO1993000910A1 (en)	1991-07-12	1993-01-21	Vical, Inc.	Antiviral liponucleosides: treatment of hepatitis b
US5554728A (en)	1991-07-23	1996-09-10	Nexstar Pharmaceuticals, Inc.	Lipid conjugates of therapeutic peptides and protease inhibitors
AU6402594A (en) *	1993-03-10	1994-09-26	Wellcome Foundation Limited, The	Tumor targeting with l-enantiomeric oligonucleotide conjugates of immunoreagents and of chelated radionuclides
GB9307043D0 (en) *	1993-04-05	1993-05-26	Norsk Hydro As	Chemical compounds
JP3693357B2 (en)	1993-04-09	2005-09-07	峯郎実吉	Reverse transcriptase inhibitor
EP0746319A4 (en)	1993-05-12	1997-11-05	Karl Y Hostetler	Acyclovir derivatives for topical use
US5627160A (en) *	1993-05-25	1997-05-06	Yale University	L-2',3'-dideoxy nucleoside analogs as anti-hepatitis B (HBV) and anti-HIV agents
AU7954694A (en) *	1993-09-10	1995-03-27	Centre National De La Recherche Scientifique (Cnrs)	Nucleosides with anti-hepatitis b virus activity
US5587362A (en)	1994-01-28	1996-12-24	Univ. Of Ga Research Foundation	L-nucleosides
WO1996011204A1 (en) *	1994-10-07	1996-04-18	Max-Delbrück-Centrum für Molekulare Medizin	NOVEL β-L-NUCLEOSIDES AND THEIR USE
US5559101A (en)	1994-10-24	1996-09-24	Genencor International, Inc.	L-ribofuranosyl nucleosides
US5696277A (en)	1994-11-15	1997-12-09	Karl Y. Hostetler	Antiviral prodrugs
JP4413996B2 (en) *	1995-06-07	2010-02-10	エモリー・ユニバーシティ	Nucleoside having anti-hepatitis B virus activity
US6025335A (en) *	1995-09-21	2000-02-15	Lipitek International, Inc.	L-Nucleoside Dimer Compounds and therapeutic uses
WO1999045935A1 (en) *	1998-03-11	1999-09-16	Lipitek International, Inc.	Novel nucleoside analogs and uses in treating disease
BR9911457A (en)	1998-06-24	2001-12-11	Univ Emory	Use of 3'-azide-2 ', 3'-dideoxyuridine in combination with additional anti-HIV drugs for the manufacture of a drug for the treatment of HIV
ES2579903T3 (en) *	1998-08-10	2016-08-17	Centre National De La Recherche Scientifique (Cnrs)	Beta-L-2'-deoxy-nucleosides for the treatment of hepatitis B
US6444652B1 (en) *	1998-08-10	2002-09-03	Novirio Pharmaceuticals Limited	β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
MY164523A (en) *	2000-05-23	2017-12-29	Univ Degli Studi Cagliari	Methods and compositions for treating hepatitis c virus
US6787526B1 (en) *	2000-05-26	2004-09-07	Idenix Pharmaceuticals, Inc.	Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
IL153078A0 (en) *	2000-05-26	2003-06-24	Idenix Cayman Ltd	Methods for treating hepatitis delta virus infection with beta-l-2' deoxy nucleosides
WO2001092282A2 (en) *	2000-05-26	2001-12-06	Idenix (Cayman) Limited	Methods and compositions for treating flaviviruses and pestiviruses

1999
- 1999-08-10 ES ES10184657.4T patent/ES2579903T3/en not_active Expired - Lifetime
- 1999-08-10 DE DE69929060T patent/DE69929060T2/en not_active Expired - Lifetime
- 1999-08-10 DK DK10184657.4T patent/DK2415776T3/en active
- 1999-08-10 WO PCT/US1999/018149 patent/WO2000009531A2/en active IP Right Grant
- 1999-08-10 KR KR1020057009515A patent/KR100568035B1/en not_active Expired - Lifetime
- 1999-08-10 CN CNB021265739A patent/CN100482236C/en not_active Expired - Lifetime
- 1999-08-10 PT PT101846574T patent/PT2415776T/en unknown
- 1999-08-10 PT PT4075926T patent/PT1431304E/en unknown
- 1999-08-10 ES ES04075926.8T patent/ES2531928T3/en not_active Expired - Lifetime
- 1999-08-10 ES ES99941027T patent/ES2255295T3/en not_active Expired - Lifetime
- 1999-08-10 BR BRPI9912896A patent/BRPI9912896B8/en not_active IP Right Cessation
- 1999-08-10 KR KR1020067007301A patent/KR100691737B1/en not_active Expired - Lifetime
- 1999-08-10 AU AU54757/99A patent/AU5475799A/en not_active Abandoned
- 1999-08-10 US US09/371,747 patent/US6395716B1/en not_active Expired - Lifetime
- 1999-08-10 CN CNB2004100028639A patent/CN100387237C/en not_active Expired - Lifetime
- 1999-08-10 JP JP2000564981A patent/JP4294870B2/en not_active Expired - Lifetime
- 1999-08-10 EP EP10184657.4A patent/EP2415776B1/en not_active Expired - Lifetime
- 1999-08-10 DK DK04075926T patent/DK1431304T3/en active
- 1999-08-10 RU RU2006147216/04A patent/RU2424016C2/en active Protection Beyond IP Right Term
- 1999-08-10 KR KR1020067007304A patent/KR100702230B1/en not_active Expired - Lifetime
- 1999-08-10 EP EP99941027A patent/EP1104436B1/en not_active Expired - Lifetime
- 1999-08-10 DK DK99941027T patent/DK1104436T3/en active
- 1999-08-10 MX MXPA01001507A patent/MXPA01001507A/en active IP Right Grant
- 1999-08-10 CN CNB998095532A patent/CN1257912C/en not_active Expired - Lifetime
- 1999-08-10 CA CA002340156A patent/CA2340156C/en not_active Expired - Lifetime
- 1999-08-10 DE DE200712000062 patent/DE122007000062I1/en active Pending
- 1999-08-10 SG SG200302078-1A patent/SG132498A1/en unknown
- 1999-08-10 AT AT99941027T patent/ATE313550T1/en active
- 1999-08-10 KR KR1020017001758A patent/KR100634342B1/en not_active Expired - Lifetime
2001
- 2001-12-14 US US10/022,276 patent/US6569837B1/en not_active Expired - Lifetime
2003
- 2003-05-13 US US10/438,167 patent/US20030225028A1/en not_active Abandoned
2005
- 2005-09-22 US US11/232,818 patent/US7304043B2/en not_active Expired - Lifetime
2007
- 2007-05-07 JP JP2007122896A patent/JP2007269798A/en active Pending
- 2007-07-18 LU LU91348C patent/LU91348I2/en unknown
- 2007-08-06 CY CY200700017C patent/CY2007017I1/en unknown
- 2007-08-09 NL NL300286C patent/NL300286I2/en unknown
- 2007-09-21 FR FR07C0046C patent/FR07C0046I2/en active Active
- 2007-10-30 US US11/929,807 patent/US20080064655A1/en not_active Abandoned
2015
- 2015-03-02 CY CY20151100218T patent/CY1116988T1/en unknown

Also Published As

Publication number	Publication date
KR20050062664A (en)	2005-06-23
CN100482236C (en)	2009-04-29
HK1097776A1 (en)	2007-07-06
CN1478483A (en)	2004-03-03
JP2007269798A (en)	2007-10-18
DK2415776T3 (en)	2016-07-04
DE122007000062I1 (en)	2007-12-20
CN1606983A (en)	2005-04-20
CN1257912C (en)	2006-05-31
KR100568035B1 (en)	2006-04-07
DE69929060D1 (en)	2006-01-26
PT2415776T (en)	2016-07-07
US7304043B2 (en)	2007-12-04
KR100691737B1 (en)	2007-03-12
ES2255295T3 (en)	2006-06-16
CY2007017I2 (en)	2009-11-04
SG132498A1 (en)	2007-06-28
CY2007017I1 (en)	2009-11-04
HK1034083A1 (en)	2001-10-12
PT1431304E (en)	2015-03-09
RU2424016C2 (en)	2011-07-20
EP1104436A2 (en)	2001-06-06
US6395716B1 (en)	2002-05-28
NL300286I2 (en)	2008-01-02
WO2000009531A2 (en)	2000-02-24
EP2415776B1 (en)	2016-05-25
BRPI9912896B8 (en)	2021-05-25
CN100387237C (en)	2008-05-14
CA2340156C (en)	2007-10-23
ES2579903T3 (en)	2016-08-17
ES2531928T3 (en)	2015-03-20
RU2006147216A (en)	2008-07-10
KR100702230B1 (en)	2007-04-03
KR100634342B1 (en)	2006-10-16
KR20060035817A (en)	2006-04-26
US6569837B1 (en)	2003-05-27
US20030225028A1 (en)	2003-12-04
BRPI9912896B1 (en)	2016-08-09
DK1431304T3 (en)	2015-03-02
CN1320128A (en)	2001-10-31
BR9912896A (en)	2002-02-13
LU91348I2 (en)	2007-09-18
US20080064655A1 (en)	2008-03-13
CY1116988T1 (en)	2017-04-05
ATE313550T1 (en)	2006-01-15
AU5475799A (en)	2000-03-06
KR20010072392A (en)	2001-07-31
NL300286I1 (en)	2007-10-01
CA2340156A1 (en)	2000-02-24
LU91348I9 (en)	2018-12-31
DK1104436T3 (en)	2006-04-03
MXPA01001507A (en)	2003-09-10
US20060084624A1 (en)	2006-04-20
DE69929060T2 (en)	2006-08-31
JP4294870B2 (en)	2009-07-15
EP1104436B1 (en)	2005-12-21
HK1111913A1 (en)	2008-08-22
EP2415776A1 (en)	2012-02-08
KR20060038483A (en)	2006-05-03
JP2002522552A (en)	2002-07-23
FR07C0046I1 (en)	2007-10-26
WO2000009531A3 (en)	2000-06-15

Publication	Publication Date	Title
FR07C0046I2 (en)	2008-05-09	BETA-L-2'-DESOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B
FR12C0077I2 (en)	2013-08-16	Composition for the treatment of genital warts
CH1143977H1 (en)	2007-02-15	2-Oxy-benzoxazine-4-ones for the treatment of obesity
DE69731674T8 (en)	2005-09-15	Silencieux d'aspiration pour compresseur
MA25823A1 (en)	2003-07-01	COMPOSITIONS FOR THE TREATMENT OF WATER.
DZ2396A1 (en)	2003-06-04	Water treatment
EP1346724A4 (en)	2004-11-17	REMEDIES FOR HEPATITIS C
MA26822A1 (en)	2004-12-20	COMPOUNDS FOR THE TREATMENT OF ISCHEMIA.
DZ3014A1 (en)	2004-03-27	Medicines for the treatment of hypertension.
MA25411A1 (en)	2002-04-01	ATTENUATED MICROORGANISMS FOR THE TREATMENT OF INFECTION.
MA26950A1 (en)	2004-12-20	NEW RETINOIDS FOR THE TREATMENT OF EMPHYSEMA
FR2722681B1 (en)	1997-03-28	MEN'S BABY
FR2771297B1 (en)	2000-02-11	TWO-CHANNEL PROBE FOR TREATING EYEWEEDING
FR2758465B1 (en)	1999-04-09	COMPOSITION FOR THE TREATMENT OF ASBESTOS
FR2746658B1 (en)	1998-06-19	IMPLANTABLE DRAINAGE VALVE FOR THE TREATMENT OF HYDROCEPHALIA
DZ1988A1 (en)	2002-07-20	Combination therapy for the treatment of winter.
FR2747398B1 (en)	1998-05-15	METHOD FOR THE SURFACE TREATMENT OF A METAL PART
MA25852A1 (en)	2003-07-01	METHOD FOR THE TREATMENT OF INFLAMMATION.
MA23837A1 (en)	1996-12-31	BENZAMIDES FOR THE TREATMENT OF NEUROLOGICAL DEGENERES
FR2775199B1 (en)	2000-03-31	COMPOSITE MATERIAL FOR THE TREATMENT OF PHOTOGRAPHIC EFFLUENTS
FR2751637B1 (en)	1998-10-02	ELECTROCOAGULATION CELL FOR THE TREATMENT OF EFFLUENTS
EP0981545A4 (en)	2003-05-07	TREATMENT OF OSTEOPOROSIS
MA25509A1 (en)	2002-07-01	COMPOSITION FOR THE TREATMENT OF HEPATITIS C
FR2759290B1 (en)	2004-06-18	MINALCIPRAN FOR THE TREATMENT OF URINARY INCONTINENCE
EP1157694A4 (en)	2002-08-28	THERAPEUTIC AGENT FOR THE TREATMENT OF DYSERECTION